Domagoj Vucic - Senior Fellow, Immunology Discovery, Drug Discovery

Domagoj Vucic

Senior Fellow, Immunology Discovery, Drug Discovery

Postdoc Mentor
Fellow
"Blocking cell death to prevent tissue damage"
26
Years at Genentech
109
Publications at Genentech

My laboratory studies the biological role of regulators of cell death and signaling pathways (e.g. ubiquitination-mediated regulation of NF-κB pathways), and their involvement in cellular processes triggered by TNF family ligands and other pro-inflammatory stimuli. As part of this effort we are studying how ubiquitination, phosphorylation and other post-translational modifications affect functional properties of mediators of various signaling pathways including apoptosis, necroptosis and NF-κB activation. To this end we are exploring the therapeutic potential of targeting select kinases and ubiquitin ligases for the treatment of uncontrolled inflammatory responses and/or enhancement of the survival of damaged tissues.

Postdoctoral Mentor

I cherish the opportunity to coach young scientists and guide their energy and enthusiasm for science into well organized thoughts and carefully planned experiments that will lay the foundation for their future scientific careers.

Featured Publication

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.

Cell Death Differ. 2016 Sep 1;23(9):1565-76.

Newton K, Dugger DL, Maltzman A, Greve JM, Hedehus M, Martin-McNulty B, Carano RA, Cao TC, van Bruggen N, Bernstein L, Lee WP, Wu X, DeVoss J, Zhang J, Jeet S, Peng I, McKenzie BS, Roose-Girma M, Caplazi P, Diehl L, Webster JD, Vucic D.